The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

Pfizer 's (PFE -0.28%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

We upgraded the rating for Pfizer (PFE) stock, citing positive trends within the company and in the market, despite recent drop after Q2 earnings. Learn more here.

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results.

Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion stake may spark a turnaround.

Firstly, let us look at Pfizer’s stock performance in recent years. PFE stock has faced a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 45% ...